Article

Jevtana's Toxicity Profile Makes It a Good Option in Metastatic Prostate Cancer

When other therapies have failed, patients with metastatic prostate cancer who were treated with Jevtana (cabazitaxel) in the third-line setting experienced a toxicity profile similar to that of androgen-targeted therapies, making the chemotherapy agent a valid choice for some patients, according to results from the CARD trial.

When other therapies have failed, patients with metastatic prostate cancer who were treated with Jevtana (cabazitaxel) in the third-line setting experienced a toxicity profile similar to that of androgen-targeted therapies, making the chemotherapy agent a valid choice for some patients, according to results from the CARD trial.

At the European Society of Medical Oncology (ESMO) Congress 2019, CURE spoke with Dr. Arash Rezazadeh Kalebasty, a medical oncologist at Norton Cancer Institute, about the results of the trial and what Jevtana offers patients with metastatic castration-resistant prostate cancer.

Transcript:

One important outcome was the grade 3 and higher toxicities were not really very much higher than in the androgen-targeted therapy arm. I think this is very encouraging because in this population, toxicity matters. A lot of patients are elderly.

The specifics for this trial did exclude patients who were not a good candidate for chemotherapy anyway, but we have to be careful about the benefit versus risk when we offer patients chemotherapy as well.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.